Bone disease associated with antiepileptic drugs

Article Type
Changed
Tue, 10/30/2018 - 12:18
Display Headline
Bone disease associated with antiepileptic drugs
Article PDF
Author and Disclosure Information

Alison M. Pack, MD
Neurological Institute, Columbia Presbyterian Medical Center, New York, NY

Barry Gidal, PharmD
University of Wisconsin, Madison, WI

Blanca Vazquez, MD
New York University School of Medicine, New York, NY

Correspondence: Alison M. Pack, MD, The Neurological Institute, Columbia Presbyterian Medical Center, 710 W. 168th Street, New York, NY 10032; e-mail: [email protected]

Dr. Pack receives grants/research support from GlaxoSmithKline, Novartis, UCB Pharma, and Cyberonics, and has received honoraria from GlaxoSmithKline, Novartis, Ortho-McNeil, and Elan.

Dr. Gidal receives grants/research support from GlaxoSmithKline and UCB Pharma; is a consultant for GlaxoSmithKline, UCB Pharma, and Ivax; and has received honoraria from GlaxoSmithKline, UCB Pharma, and Novartis.

Dr. Vazquez receives grants/research support from, is a consultant for, and has received honoraria from Abbott, UCB Pharma, Elan, Novartis, Schwarz Pharma, GlaxoSmithKline, Ortho-McNeil, and Pfizer.

Publications
Page Number
S42-S48
Author and Disclosure Information

Alison M. Pack, MD
Neurological Institute, Columbia Presbyterian Medical Center, New York, NY

Barry Gidal, PharmD
University of Wisconsin, Madison, WI

Blanca Vazquez, MD
New York University School of Medicine, New York, NY

Correspondence: Alison M. Pack, MD, The Neurological Institute, Columbia Presbyterian Medical Center, 710 W. 168th Street, New York, NY 10032; e-mail: [email protected]

Dr. Pack receives grants/research support from GlaxoSmithKline, Novartis, UCB Pharma, and Cyberonics, and has received honoraria from GlaxoSmithKline, Novartis, Ortho-McNeil, and Elan.

Dr. Gidal receives grants/research support from GlaxoSmithKline and UCB Pharma; is a consultant for GlaxoSmithKline, UCB Pharma, and Ivax; and has received honoraria from GlaxoSmithKline, UCB Pharma, and Novartis.

Dr. Vazquez receives grants/research support from, is a consultant for, and has received honoraria from Abbott, UCB Pharma, Elan, Novartis, Schwarz Pharma, GlaxoSmithKline, Ortho-McNeil, and Pfizer.

Author and Disclosure Information

Alison M. Pack, MD
Neurological Institute, Columbia Presbyterian Medical Center, New York, NY

Barry Gidal, PharmD
University of Wisconsin, Madison, WI

Blanca Vazquez, MD
New York University School of Medicine, New York, NY

Correspondence: Alison M. Pack, MD, The Neurological Institute, Columbia Presbyterian Medical Center, 710 W. 168th Street, New York, NY 10032; e-mail: [email protected]

Dr. Pack receives grants/research support from GlaxoSmithKline, Novartis, UCB Pharma, and Cyberonics, and has received honoraria from GlaxoSmithKline, Novartis, Ortho-McNeil, and Elan.

Dr. Gidal receives grants/research support from GlaxoSmithKline and UCB Pharma; is a consultant for GlaxoSmithKline, UCB Pharma, and Ivax; and has received honoraria from GlaxoSmithKline, UCB Pharma, and Novartis.

Dr. Vazquez receives grants/research support from, is a consultant for, and has received honoraria from Abbott, UCB Pharma, Elan, Novartis, Schwarz Pharma, GlaxoSmithKline, Ortho-McNeil, and Pfizer.

Article PDF
Article PDF
Page Number
S42-S48
Page Number
S42-S48
Publications
Publications
Article Type
Display Headline
Bone disease associated with antiepileptic drugs
Display Headline
Bone disease associated with antiepileptic drugs
Citation Override
Cleveland Clinic Journal of Medicine 2004 February;71(suppl 2):S42-S48
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media